CompletedPhase 2

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

United States153 participantsStarted 2023-02-28

Plain-language summary

This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris

Who can participate

Age range9 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. LASER, light or other energy-based therapy (e.g., intense pulsed light \[IPL\], PDT; 12 weeks
✕. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester \[SADBE\], etc.), retinoids, hydrogen peroxide; 12 weeks
✕. Cryotherapy, biopsy, electrodessication, curettage, antimetabolite therapy (e.g., 5- fluorouracil), cantharidin, or any other treatment that in the opinion of the Investigator may affect the Target Lesion; 6 weeks
✕. Over-the-counter (OTC) wart therapies, paring ± occlusion; 1 week

What they're measuring

Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period

Timeframe: Baseline up to Day 134

Trial details

NCT IDNCT05799157

SponsorVeradermics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-25

View on ClinicalTrials.gov More Verruca Vulgaris trials